Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, centrisol and renasol hemodialysis concentrates, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. Its hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. In addition, the company offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan. Show more
30142 South Wixom road, Wixom, MI, 48393, United States
Start AI Chat
Market Cap
36.29M
52 Wk Range
$0.78 - $2.10
Previous Close
$0.92
Open
$0.91
Volume
168,952
Day Range
$0.89 - $0.95
Enterprise Value
37.25M
Cash
23.71M
Avg Qtr Burn
-1.307M
Insider Ownership
12.43%
Institutional Own.
8.92%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Triferic (ferric pyrophosphate citrate) Details Anemia (hemodialysis dependent chronic kidney disease) | Approved Quarterly sales | |
Triferic® AVNU (ferric pyrophosphate citrate) Details Chronic kidney disease, Psoriasis, Kidney disease | Approved Quarterly sales |
